St. Louis Chapter Meeting with Guest Speakers

Fran Sverdrup and Dr. Weihl will be presenting. Fran will be speaking about the current state of research (p38 inhibitors for FSHD: Turning off DUX4).  Dr. Conrad C. Weihl, MD, PhD, Washington University School of Medicine, Division of Adult Neurology, will be presenting an update on the Fulcrum clinical trial; Phase 2b ReDUX4 trial.  Oliver Doerr, from the St. Louis trial site will also be available to answer questions.